Skip to content

Contingency Management for Stimulant Use Disorders

Contingency Management for Stimulant Use Disorders

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05097547
Enrollment
30
Registered
2021-10-28
Start date
2021-10-31
Completion date
2022-04-30
Last updated
2021-10-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Contingency Management, Stimulant Use

Brief summary

The invetigators' objective is to implement Medication Assisted Treatment (MAT) and contingency management in patients affected by co-occurring opioid use disorder and stimulant use disorder. Participants will continue to receive standard of care for their opioid use disorder via MAT at our Outpatient Based Opioid Treatment (OBOT) Clinic. Participants' stimulant use disorder will be targeted through contingency management, with twice weekly urine drug screens and monetary prizes in exchange for negative urine drug screens. Through regular clinic visits and the use of incentives, the investigators hope to increase treatment adherence and increase the number of negative urine drug screens in subjects struggling with co-morbid opioid use disorder and stimulant use disorder. The investigators will determine whether or not this treatment is effective in this population, versus conventional treatment (baseline therapy patients were getting through OBOT). The investigators' primary outcome measure will be stimulant abstinence duration during the twelve week study.

Interventions

BEHAVIORALContingency Management

Contingency management involves receiving monetary prizes in exchange for negative urine drug screens.

Sponsors

University of Virginia
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Age 18 and older * Patients treated for opioid use disorder in the Outpatient Based Opioid Treatment (OBOT) Clinic and who also struggle with stimulant use disorder but failed conventional treatment (positive urine drug screen for substances other than THC and buprenorphine) * Ideal candidates will test positive for 3 out of 4 weeks or more prior to starting contingency management

Exclusion criteria

* Persons under the age of 18 * Persons not able to attend follow-up clinic visits * Persons not able to consent

Design outcomes

Primary

MeasureTime frameDescription
stimulant abstinence12 weeksDuration of stimulant abstinence based on urine drug screens

Contacts

Primary ContactNassima Ait-Daoud Tiouririne, MD
NAT7B@hscmail.mcc.virginia.edu(434)243-0563

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026